Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K i of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC 50 of 680 nM Form:Solid IC50& Target:Ki: 1.2 μM (PPARγ LBD),EC: 680 nM (PPARγ LBD) (Leriglitazone)